Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘A2A adenosine receptor’

Washington DC – this is our final daily post from the 2017 annual meeting of the American Association for Cancer Research (AACR).

Starting on Monday we’ll be writing up expert interviews and providing commentary and analysis around some of the sessions we went to and the data we heard.

Tuesday at AACR17 was a day when the Corvus Pharmaceuticals stock dropped 50% following presentation of preliminary clinical data for their A2A receptor antagonist CPI-444.

It’s hard not to be disappointed when you see the waterfall plots skewed to the left and above the X axis, but we really don’t have enough data yet to determine whether CPI-444 on it’s own or in combination with atezolizumab may offer benefit to some cancer patients and if so, which ones.

The company have expanded the renal (RCC) and lung cohorts (NSCLC) in their initial trial, and they’ve told us to expect more data at ASCO17 in a few weeks time. Small cap biotech stocks can be a roller coaster when it comes to data presentations at major medical/scientific meetings.

What else caught our attention in the sessions we attended on Tuesday at #AACR17?

Subscribers can login to read more or you can purchase access below. If for anyone reason you can’t see the blue purchase box, please try a different browser.

New York – at the CRI-CIMT-EATI-AACR international cancer immunotherapy conference (Twitter #CICON16) that’s currently underway, one of the plenary oral presentations and posters that attracted my attention was for CPI-444, a small molecule inhibitor of the adenosine 2 A receptor (A2AR). It is in development by Corvus Pharmaceuticals (NASDAQ: CRVS).

Corvus Pharmaceuticals Logo

Stephen Willingham, PhD a Senior Scientist at Corvus presented data yesterday on CPI-444, “A potent & selective inhibitor of the A2AR that induces antitumor responses alone and in combination with anti PD-L1 in preclinical and biomarker studies.”  

Corvus announced a collaboration with Genentech back in October 2015. A phase 1 trial with CPI-444 alone and in combination with Genentech’s anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) is now underway.

Targeting the tumor microenvironment to lower the immunosuppressive adenosine and improve checkpoint point effectiveness could be a big win for both Corvus and Genentech if CPI-444 is able to significantly improve the response rates to atezolizumab.

Corvus Senior Scientist Stephen Willingham, PhD and Chief Business Officer Jason Coloma, PhD kindly spoke to BSB about what the data presented in New York means and the company’s clinical development strategy.

Subscribers can login to read more about their insights or you can purchase access below.